A study published in the American Journal of Infection Control (AJIC) shows a proven reduction in MRSA, fungi, and aerobic bacteria air and surface bio-burdens and a greater than 70% reduction in HAIs.
A decline in total aggregate counts of HAIs (ie, CAUTI, CLABSI, C difficile, MRSA bacteremia, and pneumonia) at both ICUs was observed when compared to a historical count 21 months prior to AP activation for the Louisiana site (71% reduction; 24 HAIs to 7 HAIs) (Fig A) and 12 months prior at the Kentucky site (70% reduction; 10 HAIs to 3 HAIs) (Fig B)
Fig. Aggregate counts of surveilled HAIs comparing matched time periods before and after ActivePure® technology activation for Louisiana (A) and Kentucky (B). CAUTI, catheter-associated urinary tract infection; C difficile, Clostridioides difficile; CLABSI, central line-associated bloodstream infection; MRSA, methicillin-resistant Staphylococcus aureus.
Mean aerobic bacterial and fungal CFUs were reduced by 72% (27.3 CFUs to 7.7 CFUs) and 89% (10.6 CFUs to 1.18 CFUs), respectively, from baseline to postactivation at Louisiana site. Mean aerobic bacterial CFUs increased by 6% (9.29 CFUs to 9.86 CFUs)1 and mean fungal CFUs were reduced by 27% (1.57 CFUs to 1.14 CFUs) at the Kentucky site.
* Illustrated findings were statistically significant.
1 Mean aerobic bacterial air CFUs at the Kentucky site were the only study result to show an increase compared to baseline, which is likely due to the turbulent nature of airflow and ensuing variability of airborne microbe dispersal.